市場調査レポート

治療クラスの概要:乾癬 - 尋常性乾癬 & 乾癬性関節炎 : 将来の治療パラダイムを変換する新しい経口薬および生物製剤

Psoriasis - Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm

発行 MP Advisors 商品コード 296611
出版日 ページ情報 英文 55 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
治療クラスの概要:乾癬 - 尋常性乾癬 & 乾癬性関節炎 : 将来の治療パラダイムを変換する新しい経口薬および生物製剤 Psoriasis - Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm
出版日: 2014年02月25日 ページ情報: 英文 55 Pages
概要

当レポートでは、乾癬の治療パイプラインにおける経口、注射および局所薬剤について調査し、それらの治験データを比較し、商業的可能性を分析しており、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 乾癬のアンメットニーズ

  • 抗TNFの限界
  • より良い効能・安全性のプロファイルを持った新規薬剤の余地

第3章 特定のアンメットニーズ・新しい治療法

  • 尋常性乾癬
  • 乾癬性関節炎

第4章 パイプライン:生物製剤

  • IL-12 および IL-23 阻害剤
  • インターロイキン-17 (IL-17) および 受容体 (IL-17RA)
  • その他の標的

第5章 パイプライン:経口療法

  • JAK-STAT標的
  • ホスホジエステラーゼ4(PDE4)阻害剤
  • その他の標的

第6章 パイプライン:局所療法

  • M518101
  • CT327
  • DRM02
  • Xantryl
  • INCB18424
  • AN2728
  • MOL4249
  • DLX105

第7章 商業的展望

第8章 疾病の概要

第9章 現在の治療選択肢

第10章 PsAの治療ガイドライン

図表

目次
Product Code: TC14022401

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients' pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients. The lack of targeted immune therapies other than TNF-α inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer launched the first oral Rheumatoid Arthritis (RA) drug -Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics. In the last couple of years, the face of healthcare has been changing due to challenges - quality and its affordability and accessibility to the providers and patients.

We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA - apremilast, Xeljanz - tofacitinib) and onwards. In this report, we highlight the novel targets - oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential!

Table of Contents

1. Executive Summary

2. Unmet Need in Psoriasis

  • 1. Limitations of Anti-TNFs
  • 2. Scope for Entrants with Better Efficacy and Safety Profiles

3. Specific Unmet Need and Emerging Therapies

  • 1. Plaque Psoriasis
  • 2. Psoriatic Arthritis

4. Pipeline - Biologics Products

  • 1. IL-12 and IL-23 inhibitors
    • 1. Stelara
    • 2. tildrakizumab (MK-3222/ SCH 900222)
    • 3. Guselkumab (CNTO 1959)
    • 4. Fezakinumab (ILV-094)
  • 2. Interleukin-17 (IL-17) and Receptor (IL-17RA)
    • 1. Secukinumab
    • 2. Ixekizumab (LY2439821)
    • 3. Brodalumab (AMG 827)
  • 3. Other Targets
    • 1. Cimzia
    • 2. Itolizumab
    • 3. Tregalizumab

5. Pipeline - Oral Treatment

  • 1. Targeting JAK-STATs
    • 1. Tofacitinib
    • 2. LY3009104
    • 3. INCB39110
    • 4. ASP015K
    • 5. GSK2586184
  • 2. Phosphodiesterases 4 (PDE4) Inhibitor
    • 1. OTEZLA
  • 3. Other Targets
    • 1. Sotrastaurin
    • 2. LAS41008
    • 3. Voclosporin
    • 4. LLL 3348
    • 5. CF101
    • 6. Ponesimod
    • 7. VB-201
    • 8. FP187
    • 9. GSK-2245840
    • 10. IMO-8400

6. Pipeline - Topical Treatments

  • 1. M518101
  • 2. CT327
  • 3. DRM02
  • 4. Xantryl
  • 5. INCB18424
  • 6. AN2728
  • 7. MOL4249
  • 8. DLX105

7. Commercial Outlook

8. Disease Overview

  • 1. Etiology and Pathophysiology of Psoriasis
  • 2. Types of Psoriasis
  • 3. Treatment Efficacy Tools

9. Current Treatment Options

10. Treatment Guidelines For PsA

TABLES

  • 1 Approved/ Marketed Products
  • 2
    • A. Psoriasis' Pipeline: Small Molecules - Oral/ Injectable
    • B. Psoriasis' Pipeline: Topical
  • 3 Psoriasis' Pipeline: Biologics
  • 4 Select Late- & Mid-Stage Pipeline: Plaque Psoriasis
  • 5 Select Late- & Mid-Stage Pipeline: Psoriatic Arthritis
  • 6 Ixekizumab: Phase III Clinical Trial Designs
  • 7 Brodalumab: Phase III Clinical Trial Designs
  • 8 Clinical Data Comparison: Plaque Psoriasis - Biologics
  • 9
    • A. Tofacitinib: PASI Improvement from Baseline
    • B. Tofacitinib: Improvement in Quality-of-Life (QOL) Measures
  • 10 Other Targets in Clinical Development for RA
  • 11 Genes Associated with Psoriasis Susceptibility
  • 12 Competitive Landscape: Plaque Psoriasis
  • 13 Competitive Landscape: Psoriatic Arthritis

FIGURES

  • 1 PFE's Xeljanz Launch vs. Other Recent RA Launches
  • 2 The Structure and Function of the Cytokines IL-12 And IL-23
  • 3 Clinical Data: ACCEPT - Head-To-Head Trial with Enbrel
  • 4 MK-3222Neutralizes IL-23, Specifically
  • 5 Immunology and Immunotherapeutic Targets of Psoriasis
  • 6 IL-17-Induced Signaling Pathways
  • 7 Ixekizumab: Clinical Response (PASI And sPGA) @ week 20
  • 8 Itolizumab Value Proposition with Marketed Products
  • 9 Regulation of JAK-STAT Signaling
  • 10 INCB39110: Response Rate - Exploratory Efficacy Analyses
  • 11 ASP015K - Changes from Baseline in PASI at Day 42
  • 12 PDE Inhibitors Crosstalk
  • 13 AEB071 - PASI 75 Reductions Compared with Baseline
  • 14 DRM02- Novel Mechanism of Action
  • 15 DLX105 - PhIa Results (PASI Changes @ Day 14)
  • 16 Psoriasis Treatment Ladder (Schematic)
  • 17 US Psoriasis Market Estimation
  • 18 Proposed Schema of the Evolution of A Psoriatic Lesion
  • 19 Distribution of Psoriasis Severity
  • 20 Use of Therapies Depending on the Disease Severity
  • 21 Targeted Therapy Classification Based on Pathogenesis
  • 22 Comparison of GRAPPA and AAD Treatment Guidelines
Back to Top